Yifan Pharmaceutical Co., Ltd.
002019.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.75B
Close$
$-5.50
158.3% downside
Current Fair Value
158.3% downsideOvervalued by 158.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.75 Billion |
|---|---|
| Enterprise Value | $13.50 Billion |
| Dividend Yield | $0.10 (1.04%) |
| Earnings per Share | $0.33 |
| Beta | 0.46 |
| Outstanding Shares | 1,216,390,085 |
Return
| Return on Equity | 3.43% |
|---|---|
| Return on Assets | 2.35% |
| Return on Invested Capital | 3.88% |
Valuation & Multiples
| P/E Ratio | 38.73 |
|---|---|
| PEG | -111.47 |
| Price to Sales | 2.36 |
| Price to Book Ratio | 1.35 |
| Enterprise Value to Revenue | 2.72 |
| Enterprise Value to EBIT | 35.26 |
| Enterprise Value to Net Income | 44 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 0.3 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 24, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Yifan Pharmaceutical Co., Ltd.
4,221 employees
CEO: Xian Feng Cheng Yifan Pharmaceutical Co., Ltd. engages in the research, development, production, sale of pharmaceutical products, active pharmaceutical ingredients and polymer materials. It provides blood tumors, gynecology, pediatrics, skin, orthopedic...